


Interrogating the antigen specific T cell recognition of cancer

Sine Reker Hadrup


Professor,

The Technical University of Denmark

Division for Immunology and Vaccinology



Neopeptide prediction



Technologies for T cell detection

Neopeptide immunogenicity


TCR fingerprinting



Mind the gap in neoepitope prediction

First and last author	Journal	Tumor type	Patients	Peptides tested	T cell responses	Test method	Peptide lengths
Robbins et al. Rosenberg	Nat Med	SKCM	3	227	10	ELISPOT	9–10
van Rooij et al. Schumacher	J Clin Oncol	SKCM	1	-	1	FLT	9
Wick et al. Nelson	Clin Cancer Res	HGSC	3	109	1	ELISPOT	8–11
Rajasagi et al. Wu	Blood	CLL	2	48	3	ELISPOT	9–10
Lu et al. Robbins	Clin Cancer Res	SKCM	2	10	2	ELISA	8–11
Snyder et al. Chan	N Engl J Med	SKCM	1	-	1	ICS	9
Rizvi et al. Chan	Science	NSCLC	1	-	1	FLT	9
Cohen et al. Robbins	J Clin Invest	SKCM	8	427	9	FLT	9–10
Kalaora et al. Samuels	Oncotarget	SKCM	1	2	1	ICS	9, 11
McGranahan et al. Swanton	Science	NSCLC	2	642	3/8	FLT / BLM	9–11
Strønen et al. Schumacher	Science	SKCM	4	56	11	FLT	9–11
Bassani-Sternberg et al. Krackhardt	Nature Commun	SKCM	1	8	2	MS-FLT	8–10,12
Bentzen et al. Hadrup	Nat Biotechnol	NSCLC	2	703	9	BLM	9–11
TOTAL			24	1874	53		


~3% of all predicted neoepitopes give rise to a T cell response

Evolution of T cell detection technologies






Design




Elongation




Amplification






Correlation to state-of-the-art method:





10 healthy donors screened with a library of 1031 pMHC complexes




Analysis of Melanoma TIL against 175 HLA-A2 shared antigen epitopes



Neopeptide recognition in NSCLC




What determines neopeptide immunogenicity?




Yarchoan M & Jaffee EM. *Nat Rev Cancer* (2017) **17**:209–222.

Neopeptide prediction



1. Identification of cancer-specific genetic alterations




NGS pipeline:

MuPeXI

(Mutant Peptide Extractor and Informer)

<http://www.cbs.dtu.dk/services/MuPeXI>

2. Neo-epitope immunogenicity




MHC binding

Gene expression level


Mutation characteristics
(position/self-similarity)

Selective advantage & genetic
heterogeneity

Neoepitopes are stronger HLA binders than neopeptides




Coulie et al. Nature Reviews. Cancer. 2014




T cell response ● NO ◆ YES Anchor position ● NO ● YES

Bjerregaard AM et al. Frontiers Imm. 2017

Loss of self-similarity contributes to immunogenicity specifically for conserved binders







Novel tools to analyze for T cell recognition using large libraries of pMHC

Understanding neoepitope immunogenicity, to improve neoepitope prediction

TCR fingerprinting

- Increased understanding of TCR-pMHC interactions
- `Rules´ for cross recognition between pMHC complexes
- Improved safety profiles of TCRs taken to the clinic






2 TCRs:

HLA-B0702 LTA (APNCYGNIPL)

HLA-B2401 LTA (EWWRSGGFSF)

12 T cell clones:

HLA-A0201 LTA (KLLEIAPNC)



2 TCRs:




HLA-B0702 LTA (APNCYGNIPL)

HLA-B2401 LTA (EWWRSGGFSF)


12 T cell clones:

HLA-A0201 LTA (KLLEIAPNC)


Alanine substitution describes only partially the TCR interaction requirements




A





B




C





TCR fingerprinting HLA-B0702 LTA (APNCYGNIPL)



Hierarchical Clustering - Dendrogram of PC1-PC12 distances with leaf logos





Patient	Clone	TRA sequence	TRB sequence	EC50
w678	1	CVLNNNDMRF	CAIRQFDANTGELFF	0,47
	1.5	unresolved by NGS	CAIRQFDANTGELFF	0,84
	2	CAFRVSHDMRF	CASSIIAGSSYNEQFF	0,01
	3	CVVATYSGGGADGLTF	CASSIIAGSSYNEQFF	0,02
	4	CVVATYSGGGADGLTF	CASSGNPSTDTQYF	0,02
w876	2	CVVTEYSGGGADGLTF	CASRGQNTGELFF	1,20
	5	CAYNQGGKLIF	CASSVLNTGELFF	0,11
	5.5	unknown alpha	CASSVLNTGELFF	0,14
	6	CVVPLYSSASKIIF	CASSDTPDLNTEAFF	0,03
	9	CVGNNNDMRF	CAIRRQDQNTGELFF	0,13
w830	4	CVLNNNDMRF	CASSILGASNQPQHF	1,10
w683	1	CVVALYSGGGADGLTF	CASRSQNYGYTF	0,83



Validation based on functional recognition


ICS following Alanine substitution, (Gly sub for pos 6)



Potential cross-recognition in the human proteasome

KLL-clone	sequence	p-value	gene	protein name
<u>5808</u>	RTCEIQGWC	1.51e-07	P2RX3	Purinergic receptor P2X 3
	KWQEIIQNC	2.48e-07	SLF2	SMC5-SMC6 complex localization factor 2
	KTVGIYPNA	2.87e-07	ST6GALNAC3	ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 3
	RLVGIHQNG	3.07e-07	WLS	Wntless Wnt ligand secretion mediator
	RNCTITANA	3.64e-07	CD27	CD27 molecule
	RTCEIWSWC	4.2e-07	P2RX6	Purinergic receptor P2X 6
	FICEICNNG	4.92e-07	PLEKHM3	Pleckstrin homology domain containing M3
	KTCEIFGWC	5.47e-07	P2RX1	Purinergic receptor P2X 1
	CVVEICPPA	5.47e-07	PXDNL	Peroxidasin like
	RQLEIANN	5.52e-07	IFT122	Intraflagellar transport 122
<u>5514</u>	NLMEVMPNI	4.14e-08	RAD9B	RAD9 checkpoint clamp component B
	TVMEVMVNV	2.39e-07	RYR1	Ryanodine receptor 1
	LVLEVDPNI	2.57e-07	KRT8	Keratin 8
	CIQEVEVNC	3.06e-07	PRAMEF25	PRAME family member 25
	LNLEVDPNI	3.63e-07	TTBK2	tau tubulin kinase 2
	KVKEVCPNV	3.77e-07	FAR2	Fatty acyl-CoA reductase 2
	IPMEILPNV	7.57e-07	GK	Glycerol kinase
	RHIEVAPQV	1.04e-06	SEPHS1	Selenophosphate synthetase 1
	RSLEVLWNV	1.11e-06	PCSK7	Proprotein convertase subtilisin/kexin type 7
	KILEICDNV	1.14e-06	TNMD	Tenomodulin

Evaluation of cross-recognition



Gene	Protein name	Organism	Function	Pathway	Tissue expression	Expressing cell types	Staining intensity
ST6GALNAC3	ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 3	Human	Sialyltransferase	Protein glycosylation	Brain	Neuronal cells	Low
					Endocrine tissue	Glandular cells	Low
					Gastrointestinal tract	Glandular cells	Low
					Breast and female reproductive system	Squamous epithelial cells	Low
					Muscle tissue	Myocytes	Medium-high

In summary

Large library screening for pMHC recognition of T cells

- Shared antigens
- Neoantigens

Identify novel antigens & understand immunogenicity

TCR fingerprinting

- Implications for clinical safety

